Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial

American Journal of Psychiatry

Volumn 160, Issue 4, 2003, Pages 741-748

  Keck Jr , Paul E ^a   Versiani, Marcio ^b   Potkin, Steven ^b   West, Scott A ^b   Giller, Earl ^b   Ice, Kathleen ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MOTOR DYSFUNCTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; ACUTE DISEASE; BIPOLAR DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HOSPITALIZATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME;

EID: 0037512369     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.4.741     Document Type: Article

References (29)

1. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD (Depakote Mania Study Group): Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271:918-924
2. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI: Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48:62-68
3. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V (Olanzapine HGEH Study Group): Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702-709
4. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A (Olanzapine HGGW Study Group): Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57:841-849
5. Goodwin FK, Murphy DL, Bunney WE Jr: Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry 1969; 21:486-496
6. Maggs R: Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963; 109:56-65
7. Schon M, Juel-Nielson N, Stromgren E, Voldby H: The treatment of manic psychoses by administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17:250-260
8. Stokes PE, Shamoian CA, Stoll PM, Patton MJ: Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; 1:1319-1325
9. Ballenger JC, Post RM: Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978; 2:159-175
10. Klein DF: Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967; 16:118-126
11. Keck PE Jr, McElroy SL: Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol 1996; 16(suppl 1):15S-23S
12. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425:197-201
13. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (Ziprasidone Study Group): Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20:491-505
14. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140:173-184
15. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN: An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18:296-304
16. Keck PE Jr, Reeves KR, Harrigan EP: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001; 21:27-35
17. Davis R, Markham A: Ziprasidone. CNS Drugs 1997; 8:153-159
18. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696
19. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, New York State Psychiatric Institute, Biometrics Research, 2001
20. Endicott J, Spitzer RL: A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1978; 35:837-844
21. Metropolitan Life Insurance Company: 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64:3-9
22. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
23. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
24. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
25. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
26. Zarate CA Jr: Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000; 61(suppl 8):52-61
27. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25:233-255
28. Collaborative Working Group on Clinical Trial Evaluations: Assessing the effects of atypical antipsychotics on negative symptoms. J Clin Psychiatry 1998; 59(suppl 12):28-34
29. Glazer WM: Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61(suppl 3):16-21